Anima Biotech

Company Overview

Snapshot

Founded in June 2014 by Yochi Slonim, M.Sc. and Zeev Smilanski, Ph.D., Anima Biotech operates with 51–200 employees. The company has raised a total of $30M across one funding round from National Institute of Health (NIH). In January 2023, Anima Biotech announced a collaboration with AbbVie for the discovery and development of mRNA biology modulators.

Business overview

Anima Biotech is a biotechnology company focused on the discovery of small-molecule mRNA drugs. The company utilizes its proprietary mRNA Lightning platform, which integrates high-scale phenotypic screening with AI-driven MOAi technology to elucidate the mechanism of action of active molecules. This approach enables Anima Biotech to develop a broad pipeline across various therapeutic areas, including fibrosis, oncology, and neuroscience. The company also engages in strategic collaborations with pharmaceutical industry partners such as Lilly, Takeda Pharmaceuticals, and AbbVie, operating within the Health Tech & Life Sciences sector.

Strategic signal

In January 2023, Anima Biotech announced a significant collaboration with AbbVie for the discovery and development of mRNA biology modulators targeting oncology and immunology. This partnership validates Anima Biotech's mRNA Lightning platform and its potential to identify novel small-molecule drugs, signaling strong industry confidence in its AI-driven drug discovery capabilities and expanding its reach into critical therapeutic areas.

Company Intelligence Q&A

What is Anima Biotech's core technology?

Anima Biotech's core technology is mRNA Lightning, a platform designed for the discovery of selective small-molecule mRNA drugs. It combines high-scale phenotypic screening with AI-driven MOAi technology to understand the mechanism of action of active molecules.

When was Anima Biotech founded and by whom?

Anima Biotech was founded in June 2014 by Yochi Slonim, M.Sc. and Zeev Smilanski, Ph.D.

What significant collaboration did Anima Biotech announce in January 2023?

In January 2023, Anima Biotech announced a collaboration with AbbVie for the discovery and development of mRNA biology modulators against oncology and immunology targets.

What was a key milestone achieved in the Takeda collaboration?

In July 2022, Anima Biotech achieved a milestone in its strategic collaboration with Takeda Pharmaceuticals, focused on discovering and developing mRNA translation modulators for neurological diseases.

What award did Anima Biotech win in 2018?

In November 2018, Anima Biotech and Eli Lilly & Co. won the US Deal of the Year Award at the LifeStars Awards.